Comparative Pharmacology
Head-to-head clinical analysis: NORPACE CR versus QUALAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE CR versus QUALAQUIN.
NORPACE CR vs QUALAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for CrCl <40 mL/min.
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)